An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/CAP Guideline-Reference-Cited by-同舟云学术

An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/CAP Guideline

Published:2022-01 Issue:1 Volume:22 Page:e114-e122
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Wang Chao,Tsang Julia Y.,Poon Ivan K.,Shao Yan,Li Joshua J.,Shea Ka-Ho,Hlaing Thazin,Wong Sio-In,Tse Gary M.

Funder

Science and Technology Planning Project of Guangdong Province

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update;Wolff;J Clin Oncol,2018

2. Biology of HER2 and its importance in breast cancer;Yarden;Oncology,2001

3. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

4. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response;de Azambuja;Lancet Oncol,2014

5. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer;Wolff;J Clin Oncol,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype;Modern Pathology;2024-08

2. HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?;Applied Immunohistochemistry & Molecular Morphology;2023-07-06

3. Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment;eBioMedicine;2023-05

4. HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons;Anti-Cancer Drugs;2023-01-24

5. Marker assessments inER‐positive breast cancers: old markers, new applications?;Histopathology;2022-08-31